Dr. Neuman is an Adjunct Professor of Pharmacology and Toxicology at the University of Toronto. She is the founder and CEO of In Vitro Drug Safety and Biotechnology in Toronto. Dr. Neuman holds a MSc. in Biology from the University of Bucharest, as well as a PhD in Physiology from the Faculty of Medicine, Tel Aviv University. Dr. Neuman completed a post-doctoral fellowship in Clinical Chemistry, Hepatology, Gastroenterology and Clinical Pharmacology at the University of Toronto. Dr. Neuman began her PhD at Tel Aviv University while working as a clinical chemist at Assaf Harofeh (now Shamir) Medical Center, as well as the community laboratory Maccabi. She came to Canada in 1990 as a postdoctoral fellow at the University of Toronto. Her fellowship in the Department of Gastroenterology at the Hospital for Sick Children in Toronto exposed her to a genetically diverse population of children. She introduced a practice specific test for pancreatic deficiencies, cystic fibrosis and nutritional disorders. In 1991 she became the Chief of the Laboratory of Gastroenterology and Nutrition at The Hospital for Sick Children. A year later, she accepted the position of the Head of the In Vitro Drug Safety Laboratory at Sunnybrook Health Sciences. Her laboratory introduced a novel Lymphocyte Toxicity Assay to determine hypersensitivity syndrome reactions due to medication or herbal supplements. This test is presently used as a clinical laboratory test to predict possible adverse reaction or drug-drug interactions. Dr. Neuman founded In Vitro Drug Safety and Biotechnology lab in 2004 in Toronto. As Executive Director and CEO, her focus is on discovering and proposing new drug targets to reduce alcohol and drugs of misuse-induced inflammation. Dr. Neuman implemented therapeutic monitoring of drugs of use containing cannabinoids. Her work is also accelerating the clinical validation of therapeutics that may reduce herbal and medication-induced damage as well as advancing the early development of new drug candidates. Her in vitro modeling technology allows accurate decision-making at critical junctures in drug development. Moreover, her laboratory investigates alternative options to reduce alcohol and non-alcoholic steatohepatitis. In addition to her clinical practice and expertise, Dr. Neuman has published extensively in the areas of clinical biochemistry, clinical toxicology, non-invasive biomarkers for liver fibrosis, inflammation and repair of inflammatory bowel disease and interaction between alcohol misuse and use of therapeutics. Dr. Neuman uses therapeutic and drug monitoring techniques as a key to personalized medicine that allows earlier detection of diseases. Throughout her career as a clinician, scientist and academic, Dr. Neuman has demonstrated her commitment to educating and training the next generation of researchers. She has lectured at the University of Toronto and has mentored graduate students, postdoctoral fellows and clinical fellows from Romania, Israel, Canada, France and Italy.